WESTPORT, Conn.--(BUSINESS WIRE)--TriStar Wellness Solutions, Inc. (OTCQB: TWSI), a health and wellness company that targets opportunities in the self-care and professional marketplace, has been awarded U.S. Patent No. 8,445,671 for the manufacturing process for m.doc™ bleeding control technology. The patent was granted to HemCon Medical Technologies Inc., a wholly owned subsidiary of TriStar Wellness Solutions, on May 21. m.doc™ technology currently serves as the basis of an OTC healthcare product line that has been marketed in the European Union and selectively in the U.S. by HemCon; the new patent gives TriStar patent protection for m.doc™ until August 30, 2028, and the company plans a comprehensive launch of m.doc™ products in the U.S. OTC market.
m.doc™ is an active hemostatic agent that works with the body’s natural coagulation system to speed up the process to stop bleeding. The active ingredient of m.doc™ is microdispensed oxidized cellulose, which is a derivative of pure natural cotton. Oxidized cellulose has been used by medical professionals to stop bleeding for over 50 years. m.doc™ is a very fine powder that rapidly absorbs the blood from minor cuts and grazes to form a soft gel-like layer over the wound and stop the bleeding quickly. The m.doc™ technology’s unique characteristics enables the product to be incorporated into many different modalities. HemCon has already incorporated the technology into a number of OTC products including nasal plugs, antibacterial gel, spray and wound pads.
“This patent presents TriStar and Hemcon with a tremendous opportunity to expand its leadership position in bleeding control in the United States,” said John Linderman, President, CEO of TriStar Wellness Solutions. “The introduction of the revolutionary m.doc™ technology into the American OTC market reinforces the significance of our recent acquisition of HemCon and will give U.S. consumers new and more effective options for controlling bleeding quickly and safely. We anticipate launching a line of m.doc™ products in the U.S. and will report on the progress of this initiative as it unfolds.”
Barry Starkman, President and CEO of HemCon and Senior Vice President of TriStar, added, “Receiving this patent is a significant milestone for HemCon, as we begin an important new phase of our growth, and realize the great potential our company has to improve existing wound care solutions. We look forward with great anticipation to incorporating m.doc™ technology into a range of new products to be introduced into the marketplace.”
About TriStar Wellness Solutions
TriStar Wellness Solutions, Inc. (TWSI) is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beauté de MamanTM brand of women’s health products. Additional information is available at www.tstarwellness.com.
Forward-Looking Statement
This press release for TriStar Wellness Solutions, Inc. contains forward-looking statements. Generally, you can identify these statements because they use words like "anticipates," "believes," "expects," "future," "intends," "plans," and similar terms. These statements reflect only our current expectations. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy and actual results may differ materially from those we anticipated due to a number of uncertainties, many of which are unforeseen, including, among others, the risks we face as described our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements which apply only as of the date of this press release. To the extent that such statements are not recitations of historical fact, such statements constitute forward-looking statements that, by definition, involve risks and uncertainties. In any forward-looking statement where we express an expectation or belief as to future results or events, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement of expectation of belief will be accomplished.
